Chronic calcifying pancreatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was concluded that PSP-S gene expression is specifically reduced in CCP patients.
|
2525567 |
1989 |
Nutrition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Composition of calculi--at least 95% calcium salts and a degraded form of lithostathine S (formerly called PSP S2-5)--was similar in the Occidental alcoholic and in the tropical form: calcified calculi are probably related to alcohol and nutritional disorders.
|
1736346 |
1992 |
Schizophrenia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It is concluded that in PSP individuals impaired attention probably results from prenatal developmental abnormalities (possibly on the cellular level) and is likely to be a marker of a biological vulnerability to schizophrenia.
|
10532621 |
1999 |
Attention Deficit Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent.
|
10532621 |
1999 |
Attention deficit hyperactivity disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent.
|
10532621 |
1999 |
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
These data provide evidence for extremely rare apoptotic neuronal death in AD and PSP compatible with the progression of neuronal degeneration in these chronic diseases.
|
11205141 |
2000 |
Liver Neoplasms, Experimental
|
0.200 |
Biomarker
|
phenotype |
RGD |
Down regulation of a novel protein, PSP, in rat hepatoma cdRLh 84-beared tumor.
|
12939504 |
2003 |
Progressive supranuclear palsy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis.
|
14502653 |
2003 |
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis.
|
14502653 |
2003 |
Corticobasal degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis.
|
14502653 |
2003 |
Bradykinesia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism.
|
14502653 |
2003 |
Presenile dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism.
|
14502653 |
2003 |
Parkinson Disease, Postencephalitic
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism.
|
14502653 |
2003 |
Dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism.
|
14502653 |
2003 |
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To review the clinical and molecular features of non-Alzheimer's disease (non-AD) dementias, focusing on disorders associated with tau pathology (that is, frontotemporal lobar degeneration [FTLD], corticobasal ganglionic degeneration [CBD], and progressive supranuclear palsy [PSP]) or on disorders with synuclein pathology (that is, dementia with Lewy bodies [DLB] and multisystem atrophy [MSA]).
|
15101498 |
2004 |
Alzheimer's Disease
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD.
|
15641585 |
2004 |
Tauopathies
|
0.050 |
Biomarker
|
group |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
Pick Disease of the Brain
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
Corticobasal degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
Senile dementia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD.
|
15641585 |
2004 |
Argyrophilic grain disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
Lewy Body Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
To review the clinical and molecular features of non-Alzheimer's disease (non-AD) dementias, focusing on disorders associated with tau pathology (that is, frontotemporal lobar degeneration [FTLD], corticobasal ganglionic degeneration [CBD], and progressive supranuclear palsy [PSP]) or on disorders with synuclein pathology (that is, dementia with Lewy bodies [DLB] and multisystem atrophy [MSA]).
|
15101498 |
2004 |
Deuteranomaly
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD.
|
15641585 |
2004 |
Progressive supranuclear palsy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have recently examined the MAPT locus in progressive supranuclear palsy and found that a haplotype (H1c) on the background of the well-described H1 clade is associated with PSP.
|
16000317 |
2005 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Due to the similarities between human CaP tumors and the PSP-KIMAP tumors, this preclinical model may supplement the current transgenic models to study CaP more accurately.
|
15727931 |
2005 |